<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99223">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02005458</url>
  </required_header>
  <id_info>
    <org_study_id>TB1309CSF</org_study_id>
    <nct_id>NCT02005458</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy</brief_title>
  <official_title>Multi-center, Randomized, Open-labeled, Positive-controlled, Phase Ⅱ Study to Evaluate Efficacy and Safety of YPEG-rhG-CSF, Once-per-cycle, Comparing to PEG-rhG-CSF, Once-per-cycle, in Chemotherapy-induced Neutropenia of Patients With Malignancies Receiving Myelosuppressive Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiamen Amoytop Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiamen Amoytop Biotech Co., Ltd.</source>
  <oversight_info>
    <authority>China: Food and Drug Administrition</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to examine which dose of YPEG-rhG-CSF, once-per-cycle, has similar efficacy
      and safety, comparing to PEG-rhG-CSF, once-per-cycle,  in chemotherapy-induced neutropenia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of Grade 3 &amp;4 neutropenia, and median duration of neutropenia in the two experimental cycles</measure>
    <time_frame>21 day</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Grade 3 and 4 neutropenia means absolute neutrophil count is less than 1000/mm3 and 500/mm3 , respectively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of febrile neutropenia in the two experimental cycles</measure>
    <time_frame>21 day</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Febrile neutropenia means absolute neutrophil count is less than 500/mm3 or absolute neutrophil count between 500/mm3 and 1000mm3 but probably to decline to less than 500mm3 within 48hrs, and body temperature is higher than 38.5 degrees celsius or higher than 38.0 degrees celsius and lasting for more than 1hr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diversification of neutrophil in the two experimental cycles</measure>
    <time_frame>21 day</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>YPEG-rhG-CSF 20μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YPEG-rhG-CSF 30μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YPEG-rhG-CSF 45μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-rhG-CSF 100μg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle</intervention_name>
    <arm_group_label>YPEG-rhG-CSF 20μg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle</intervention_name>
    <arm_group_label>YPEG-rhG-CSF 30μg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle</intervention_name>
    <arm_group_label>YPEG-rhG-CSF 45μg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle</intervention_name>
    <arm_group_label>PEG-rhG-CSF 100μg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of non-small cell lung cancer or Breast cancer, and adequate for
             carboplatin combined with taxol or cyclophosphamide combined with pharmorubicin
             chemotherapy

          -  Karnofsky Score ≥ 70

          -  Life Expectancy &gt; 3 months

          -  Age: 18～70yrs.

          -  Peripheral blood test: WBC≥3.5×106/mm3, PLT≥100×106/mm3, ANC≥1.5×106/mm3; Normal bone
             marrow function; Bone marrow biopsy shows active hematopoietic without cancer cells.

          -  Normal coagulation function, no evidences of hemorrhage tendency.

          -  No exiting diseases or condition that may influence drug absorption, distribution,
             metabolism, and excretion.

          -  Adequate liver, cardiac, kidney function. Indicators of liver function test ≤ 2.5ULN,
             Indicators of kidney function test ≤ 1ULN

          -  Understand and voluntarily sign an informed consent form.

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Evidence of tumor metastasis in bone marrow

          -  Lack insight due to tumor metastasis in the central nervous system

          -  Prior bone marrow transplant or stem cell transplant

          -  Infective symptom before enrollment into this study

          -  Other malignancy history

          -  Known hypersensitivity to any component of the drug(e.g. rh-G-CSF) that to be
             administered

          -  Subject enrolled in any other investigational drug or device trial within 3 months of
             informed consent date

          -  Drug abuser or alcoholist

          -  Prior radiotherapy or expected to received radiotherapy

          -  Unstable or uncontrolled cardiac or hypertension

          -  Other conditions which in the opinion of the investigator preclude enrollment into
             the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuankai Shi, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, CAMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuankai Shi, Ph.D</last_name>
    <phone>8610-87788701</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, CAMS</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang Runhua, Ph.D</last_name>
      <phone>86-592-6889121</phone>
      <email>clinical@amoytop.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>December 6, 2013</lastchanged_date>
  <firstreceived_date>December 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neutropenia</keyword>
  <keyword>Febrile neutropenia</keyword>
  <keyword>PEG-rhG-CSF</keyword>
  <keyword>Myelosuppressive chemotherapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
